GlassScriptPhysician profile
Stephen T Overby
NPI 1194726679
$5,805.02
in general payments reported to CMS, 2019-2025
30 companies · $950 in 2025
The $950 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,192 · 2020: $121 · 2021: $69.16 · 2022: $1,250 · 2023: $1,174 · 2024: $1,049 · 2025: $950.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,078 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,078.47 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,201.16 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $471.59 | 2019-2024 | Veozah, Myrbetriq |
| Amgen INC. | $360.25 | 2019-2025 | Otezla, Repatha, Otezla |
| Lilly USA, LLC | $333.11 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $251.72 | 2019-2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $241.34 | 2019-2025 | Breztri, Farxiga |
| Phathom Pharmaceuticals, INC. | $237.30 | 2024-2025 | Voquezna |
| Pfizer INC. | $198.39 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $187.91 | 2019-2025 | |
| Abbvie INC. | $178.60 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $152.80 | 2020-2024 | Jardiance, Ofev |
| Bayer Healthcare Pharmaceuticals INC. | $129.02 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $105.49 | 2019-2022 | |
| Glaxosmithkline, LLC. | $104.84 | 2022-2023 | Shingrix, Arexvy |
| Amarin Pharma, INC. | $99.43 | 2019-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $88.64 | 2022 | |
| Daiichi Sankyo INC. | $68.06 | 2024-2025 | Injectafer |
| Takeda Pharmaceuticals U.S.A., INC. | $56.23 | 2022 | |
| Sumitomo Pharma America, INC. | $53.93 | 2025 | Gemtesa |
| Xeris Pharmaceuticals, INC. | $47.11 | 2022-2024 | Keveyis |
| Genentech USA, INC. | $46.58 | 2019 | |
| Janssen Pharmaceuticals, INC | $37.46 | 2019-2022 | |
| Seqirus USA INC | $29.70 | 2025 | Fluad, Flucelvax |
| Merck Sharp & Dohme LLC | $27.84 | 2019-2023 | Gardasil 9, Pneumovax 23, Vaxneuvance |
| Corcept Therapeutics | $25.16 | 2019 | |
| Hologic Sales and Service, LLC | $17.63 | 2019 | |
| Currax Pharmaceuticals LLC | $15.93 | 2022 | |
| Allergan, INC. | $13.21 | 2019 | |
| Eisai INC. | $13.00 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $11.59 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Overby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.